

Title:

Real-world evidence of clinical outcomes of the use of the adalimumab biosimilar SB5 in rheumatic and digestive IMIDs: 12-month data from the PERFUSE study

Authors:

- Bruno Fautrel,
- Yoram Bouhnik,
- Carine Salliot,
- Franck Carbonnel,
- Mathurin Fumery,
- Christophe Bernardeau,
- Yves Maugars,
- Mathurin Flamant
- Fabienne Coury,
- * Ben Braithwaite,
- Janet Addison,
- On behalf of the PERFUSE investigators.

*** Corresponding Author:**

Ben Braithwaite, Sanoïa e-Health Services, Gémenos, France, 0000-0002-7378-1034

email address: bbraithwaite@sanoia.com

Supplementary Table S2: SNDS pairing statistics.

Supplementary Table S2 – B: impact of SNDS data on persistence

	< 12 months of exposure with SNDS data (N=441)	> 12 months of exposure with SNDS data (N=470)	Total (N=911)
Exposure before consideration of SNDS data			
< 12 months of exposure without SNDS data	11 (100%)	57 (25.6%)	68 (29.1%)
> 12 months of exposure without SNDS data	0 (0.0%)	166 (74.4%)	166 (70.9%)
Missing data	0	0	0